Nexium-Style Products Encourage Price Competition, FDA’s McClellan Says
Executive Summary
The availability of follow-on products like AstraZeneca's Nexium can encourage price competition within a therapeutic class, FDA Commissioner McClellan told the National Press Club Aug. 8 in Washington, D.C
You may also be interested in...
Nexium DTC Ads Criticized By CMS’ Scully During Medicaid Hearing
Direct-to-consumer advertising for follow-on drugs such as AstraZeneca's Nexium are part of the reason for "huge" Medicaid spending on prescription drugs, Centers for Medicare & Medicaid Services Administrator Thomas Scully told a House Energy & Commerce/Health Subcommittee hearing Oct. 8
Nexium DTC Ads Criticized By CMS’ Scully During Medicaid Hearing
Direct-to-consumer advertising for follow-on drugs such as AstraZeneca's Nexium are part of the reason for "huge" Medicaid spending on prescription drugs, Centers for Medicare & Medicaid Services Administrator Thomas Scully told a House Energy & Commerce/Health Subcommittee hearing Oct. 8
Mylan Launches Generic Omeprazole; Takes Risk For Purple Gold
Mylan's decision to launch the second generic version of AstraZeneca's Prilosec (omeprazole) could inject a new level of price competition into the proton pump inhibitor category